MAP2K7 and thyroid gland undifferentiated (anaplastic) carcinoma: The BRAF inhibitor dabrafenib and MEK inhibitor trametinib have achieved great success in BRAF V600E-mutated anaplastic thyroid carcinoma (ATC) (54).